Real-life experience of ceritinib in crizotinib-pretreated ALK⁺ advanced non-small cell lung cancer patients.

ABSTRACT: Here we report our experience of ceritinib in crizotinib-pretreated patients with anaplastic lymphoma kinase (ALK) positive (ALK⁺) non-small cell lung cancer (NSCLC) in a French temporary authorisation for use (TAU) study. The French TAU study included crizotinib-pretreated patients with advanced ALK⁺ or ROS proto-oncogene 1 positive (ROS1⁺) tumours. Patients received oral ceritinib (750 mg·day^-1 as a starting dose) and best tumour response (as evaluated by the investigator) and safety were reported every 3 months. A total of 242 TAUs were granted from March 12, 2013 to August 05, 2015. Of the 242 patients, 228 had ALK⁺ NSCLC and 13 had ROS1⁺ NSCLC. The median age of ALK⁺

SUBMITTER: Cadranel J 

PROVIDER: S-EPMC5810621 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature